• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

亚洲稳定型冠状动脉疾病患者接受药物洗脱支架经皮冠状动脉介入治疗时房颤的影响:一项韩国全国性研究的结果

Effect of atrial fibrillation in Asian patients undergoing percutaneous coronary intervention with drug-eluting stents for stable coronary artery disease: Results from a Korean nationwide study.

作者信息

Han Seungbong, Park Gyung-Min, Kim Yong-Giun, Hwang Ki Won, Roh Jae-Hyung, Won Ki-Bum, Ann Soe Hee, Kim Shin-Jae, Lee Sang-Gon

机构信息

Department of Applied Statistics, Gachon University, Seongnam.

Department of Cardiology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan.

出版信息

Medicine (Baltimore). 2018 Nov;97(48):e13488. doi: 10.1097/MD.0000000000013488.

DOI:10.1097/MD.0000000000013488
PMID:30508978
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6283148/
Abstract

Although the prevalence of atrial fibrillation (AF) and percutaneous coronary intervention (PCI) are increasing in Asia, there is a paucity of data concerning the effect of AF in Asian patients undergoing PCI with drug-eluting stents (DESs). Furthermore, the majority of previous studies investigating the effect of AF on prognosis following PCI have exclusively evaluated patients with myocardial infarction (MI). We aimed to evaluate the effect of AF on clinical outcomes of Asian patients undergoing PCI with DES for coronary artery disease (CAD) excluding acute MI.From national health insurance claims data in South Korea, a total of 45,288 patients aged 18 years or older without a known history of CAD, who underwent PCI with DES for the diagnosis of CAD excluding acute MI between 2011 and 2015, were enrolled. Based on the presence or absence of a history of AF at baseline, patients were categorized into the AF group (n = 1715, 3.8%) and no-AF group (n = 43,573, 96.2%). Outcomes including all-cause death, the composite outcome of all-cause death/MI/coronary revascularization, and stroke were compared between 2 groups using a propensity-score-matched analysis.After propensity-score matching, 1709 matched pairs were obtained. During the follow-up period (mean, 2.2 years), the incidence of all-cause death (hazard ratio [HR] 1.117, 95% confidence interval [CI] 0.885-1.411, P = .35) and the composite outcome of all-cause death/MI/coronary revascularization (HR 1.004, 95% CI 0.846-1.192, P = .97) were not significantly different between 2 groups. However, the incidence of stroke was significantly increased in the AF group (HR 1.983, 95% CI 1.474-2.667, P < .001).In Asian patients undergoing PCI for stable CAD, a history of AF was not associated with mortality, but was associated with increased risk of stroke.

摘要

尽管在亚洲,心房颤动(AF)的患病率和经皮冠状动脉介入治疗(PCI)的使用率都在上升,但关于AF对接受药物洗脱支架(DES)PCI治疗的亚洲患者的影响的数据却很少。此外,之前大多数研究AF对PCI术后预后影响的研究仅评估了心肌梗死(MI)患者。我们旨在评估AF对接受DES PCI治疗冠状动脉疾病(CAD,不包括急性心肌梗死)的亚洲患者临床结局的影响。

从韩国国家健康保险理赔数据中,共纳入了45288例年龄在18岁及以上、无已知CAD病史、在2011年至2015年间因诊断CAD(不包括急性心肌梗死)而接受DES PCI治疗的患者。根据基线时是否有AF病史,将患者分为AF组(n = 1715,3.8%)和非AF组(n = 43573,96.2%)。使用倾向评分匹配分析比较两组的全因死亡、全因死亡/MI/冠状动脉血运重建的复合结局以及卒中的发生率。

倾向评分匹配后,获得了1709对匹配对。在随访期间(平均2.2年),两组之间的全因死亡发生率(风险比[HR] 1.117,95%置信区间[CI] 0.885 - 1.411,P = 0.35)和全因死亡/MI/冠状动脉血运重建的复合结局(HR 1.004,95% CI 0.846 - 1.192,P = 0.97)无显著差异。然而,AF组的卒中发生率显著增加(HR 1.983,95% CI 1.474 - 2.667,P < 0.001)。

在接受PCI治疗稳定CAD的亚洲患者中,AF病史与死亡率无关,但与卒中风险增加有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7c7/6283148/6ba9eb895a2a/medi-97-e13488-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7c7/6283148/b285a2a72579/medi-97-e13488-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7c7/6283148/6ba9eb895a2a/medi-97-e13488-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7c7/6283148/b285a2a72579/medi-97-e13488-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c7c7/6283148/6ba9eb895a2a/medi-97-e13488-g003.jpg

相似文献

1
Effect of atrial fibrillation in Asian patients undergoing percutaneous coronary intervention with drug-eluting stents for stable coronary artery disease: Results from a Korean nationwide study.亚洲稳定型冠状动脉疾病患者接受药物洗脱支架经皮冠状动脉介入治疗时房颤的影响:一项韩国全国性研究的结果
Medicine (Baltimore). 2018 Nov;97(48):e13488. doi: 10.1097/MD.0000000000013488.
2
Prevalence, Management, and Long-Term (6-Year) Outcomes of Atrial Fibrillation Among Patients Receiving Drug-Eluting Coronary Stents.药物洗脱冠状动脉支架置入患者的房颤患病率、治疗及 6 年随访结果。
JACC Cardiovasc Interv. 2017 Jun 12;10(11):1075-1085. doi: 10.1016/j.jcin.2017.02.028. Epub 2017 May 17.
3
Long-term clinical outcomes after percutaneous coronary intervention for ostial/mid-shaft lesions versus distal bifurcation lesions in unprotected left main coronary artery: the DELTA Registry (drug-eluting stent for left main coronary artery disease): a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment.经皮冠状动脉介入治疗开口/中段病变与无保护左主干冠状动脉分叉病变的长期临床结局:DELTA 注册研究(左主干冠状动脉疾病药物洗脱支架):一项多中心注册研究,评估经皮冠状动脉介入治疗与冠状动脉旁路移植术治疗左主干的疗效。
JACC Cardiovasc Interv. 2013 Dec;6(12):1242-9. doi: 10.1016/j.jcin.2013.08.005.
4
Routine angiographic follow-up versus clinical follow-up in patients with multivessel coronary artery diseases following percutaneous coronary intervention with drug-eluting stents: a nested case-control study within a Korean population.药物洗脱支架经皮冠状动脉介入治疗后多支冠状动脉疾病患者的常规血管造影随访与临床随访:韩国人群中的一项巢式病例对照研究
Coron Artery Dis. 2017 Jun;28(4):307-314. doi: 10.1097/MCA.0000000000000479.
5
Revascularization in Patients With Multivessel Coronary Artery Disease and Chronic Kidney Disease: Everolimus-Eluting Stents Versus Coronary Artery Bypass Graft Surgery.多支冠状动脉疾病合并慢性肾脏病患者的血运重建:依维莫司洗脱支架与冠状动脉旁路移植术的比较
J Am Coll Cardiol. 2015 Sep 15;66(11):1209-1220. doi: 10.1016/j.jacc.2015.06.1334.
6
[Comparison on the long-term outcomes post percutaneous coronary intervention or coronary artery bypass grafting for bifurcation lesions in unprotected left main coronary artery].[经皮冠状动脉介入治疗或冠状动脉旁路移植术治疗无保护左主干冠状动脉分叉病变的长期预后比较]
Zhonghua Xin Xue Guan Bing Za Zhi. 2017 Jan 25;45(1):19-25. doi: 10.3760/cma.j.issn.0253-3758.2017.01.005.
7
Drug-eluting stents versus coronary artery bypass grafting for left-main coronary artery disease.药物洗脱支架与冠状动脉旁路移植术治疗左主干冠状动脉疾病的比较
Catheter Cardiovasc Interv. 2018 Mar 1;91(4):697-709. doi: 10.1002/ccd.27235. Epub 2017 Aug 11.
8
Everolimus-eluting stents or bypass surgery for multivessel coronary disease.依维莫司洗脱支架或旁路手术治疗多支冠状动脉疾病。
N Engl J Med. 2015 Mar 26;372(13):1213-22. doi: 10.1056/NEJMoa1412168. Epub 2015 Mar 16.
9
Impact of atrial fibrillation on clinical outcomes among patients with coronary artery disease undergoing revascularisation with drug-eluting stents.房颤对接受药物洗脱支架血运重建的冠心病患者临床结局的影响。
EuroIntervention. 2013 Jan 22;8(9):1061-71. doi: 10.4244/EIJV8I9A163.
10
Outcomes in relation to antithrombotic therapy among patients with atrial fibrillation after percutaneous coronary intervention.经皮冠状动脉介入治疗后心房颤动患者抗栓治疗的结局。
PLoS One. 2020 Oct 15;15(10):e0240161. doi: 10.1371/journal.pone.0240161. eCollection 2020.

引用本文的文献

1
Comparison of new implantation of cardiac implantable electronic device between tertiary and non-tertiary hospitals: a Korean nationwide study.三级和非三级医院心脏植入式电子设备新植入的比较:一项韩国全国性研究。
Sci Rep. 2021 Mar 15;11(1):3705. doi: 10.1038/s41598-021-83160-w.

本文引用的文献

1
CAD Is an Independent Risk Factor for Stroke Among Patients With Atrial Fibrillation.在心房颤动患者中,冠心病是中风的独立危险因素。
J Am Coll Cardiol. 2018 Nov 13;72(20):2540-2542. doi: 10.1016/j.jacc.2018.08.1046. Epub 2018 Aug 26.
2
Trends, Characteristics, and Clinical Outcomes of Patients Undergoing Percutaneous Coronary Intervention in Korea between 2011 and 2015.2011年至2015年韩国接受经皮冠状动脉介入治疗患者的趋势、特征及临床结局
Korean Circ J. 2018 Apr;48(4):310-321. doi: 10.4070/kcj.2017.0359.
3
The Global Burden of Atrial Fibrillation and Stroke: A Systematic Review of the Clinical Epidemiology of Atrial Fibrillation in Asia.
全球心房颤动和中风负担:亚洲心房颤动临床流行病学的系统评价。
Chest. 2017 Oct;152(4):810-820. doi: 10.1016/j.chest.2017.03.048. Epub 2017 Apr 17.
4
Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy.接受抗凝治疗的心房颤动患者的颅内出血。
Blood. 2017 Jun 1;129(22):2980-2987. doi: 10.1182/blood-2016-08-731638. Epub 2017 Mar 29.
5
Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis.心房颤动与心血管疾病、肾脏疾病和死亡风险:系统评价和荟萃分析。
BMJ. 2016 Sep 6;354:i4482. doi: 10.1136/bmj.i4482.
6
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.2016年欧洲心脏病学会(ESC)与欧洲心胸外科学会(EACTS)合作制定的心房颤动管理指南。
Eur Heart J. 2016 Oct 7;37(38):2893-2962. doi: 10.1093/eurheartj/ehw210. Epub 2016 Aug 27.
7
Outcomes of Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.接受经皮冠状动脉介入治疗的心房颤动患者的结局。
J Am Coll Cardiol. 2016 Aug 30;68(9):895-904. doi: 10.1016/j.jacc.2016.05.085.
8
Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.全球、地区和国家按年龄、性别划分的 240 种死因的全死因和特定死因死亡率,1990-2013 年:2013 年全球疾病负担研究的系统分析。
Lancet. 2015 Jan 10;385(9963):117-71. doi: 10.1016/S0140-6736(14)61682-2. Epub 2014 Dec 18.
9
Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation.华法林或利伐沙班抗凝治疗的心房颤动患者颅内出血:每日口服利伐沙班与维生素 K 拮抗剂预防心房颤动的卒中及栓塞的疗效比较(ROCKET AF)研究。
Stroke. 2014 May;45(5):1304-12. doi: 10.1161/STROKEAHA.113.004506. Epub 2014 Apr 17.
10
Stroke prevention in atrial fibrillation: an Asian perspective.心房颤动的卒中预防:亚洲视角
Thromb Haemost. 2014 May 5;111(5):789-97. doi: 10.1160/TH13-11-0948. Epub 2014 Feb 6.